Geneos Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Geneos Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.15K	Hold	90	–	–	﹤0.01%	2177
2026 Q1	$5.08K	Hold	90	–	–	﹤0.01%	2158
2025 Q4	$5.35K	Buy	90 +60	+200%	+$3.27K	﹤0.01%	2121
2025 Q3	$1.63K	Sell	30 -297	-91%	-$17K	﹤0.01%	2349
2025 Q2	$18K	Buy	327 +30	+10%	+$1.77K	﹤0.01%	2079
2025 Q1	$21K	Buy	297 +211	+245%	+$14.2K	﹤0.01%	1924
2024 Q4	$5.65K	Sell	86 -4	-4%	-$268	﹤0.01%	2289
2024 Q3	$6.33K	Buy	+90	New	+$7.52K	﹤0.01%	1990
2024 Q2	–	Sell	-24	Closed	-$2.1K	–	2069
2024 Q1	$2.1K	Buy	+24	New	+$2.15K	﹤0.01%	1892
2021 Q2	–	Sell	-1,277	Closed	-$99K	–	2875
2021 Q1	$99K	Buy	+1,277	New	+$104K	﹤0.01%	1315
2019 Q2	–	Sell	-49	Closed	-$4K	–	2490
2019 Q1	$4K	Hold	49	–	–	﹤0.01%	2073
2018 Q4	$4K	Buy	49 +19	+63%	+$1.81K	﹤0.01%	2026
2018 Q3	$2K	Hold	30	–	–	﹤0.01%	2236
2018 Q2	$2K	Hold	30	–	–	﹤0.01%	2089
2018 Q1	$2K	Hold	30	–	–	﹤0.01%	2012
2017 Q4	$2K	Hold	30	–	–	﹤0.01%	2004
2017 Q3	$2K	Hold	30	–	–	﹤0.01%	1952
2017 Q2	$2K	Hold	30	–	–	﹤0.01%	1904
2017 Q1	$2K	Sell	30 -13	-30%	-$1.16K	﹤0.01%	1860
2016 Q4	$3K	Hold	43	–	–	﹤0.01%	1741
2016 Q3	$3K	Sell	43 -7	-14%	-$659	﹤0.01%	1676
2016 Q2	$4K	Hold	50	–	–	﹤0.01%	1550
2016 Q1	$4K	Buy	+50	New	+$4.07K	﹤0.01%	1529

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geneos Wealth Management's BMRN Position: Q2 2026 in Review

Geneos Wealth Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 90 shares worth $5.15K. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

Geneos Wealth Management first reported a position in BMRN in Q1 2016 and has held it in 23 quarters since. The position peaked at $99K in Q1 2021. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Geneos Wealth Management held 90 shares of BioMarin Pharmaceuticals worth $5.15K as of Q2 2026.
Geneos Wealth Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #2177 holding.
Geneos Wealth Management first reported a position in BioMarin Pharmaceuticals in Q1 2016 and has held it in 23 quarters since.
Geneos Wealth Management's BioMarin Pharmaceuticals position peaked at $99K in Q1 2021.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.